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Definition  
Gastroesophageal reflux disease (GERD) is a chronic digestive 
disease that affects the lower esophageal sphincter (LES) with 
development of its incompetence and reflux of gastric contents 
into the esophagus, causing symptoms (e.g., the taste of acid in 
the back of the mouth, heartburn, bad breath, chest pain, 
vomiting, breathing problems, wearing away of the teeth) with 
or without associated esophageal mucosal injury (i.e., 
esophagitis, esophageal strictures, and Barrett's esophagus). 
Epidemiology 1   
• GERD is prevalent worldwide 
• The range of GERD prevalence estimates is (18-28)% in North 
America, (9-26)% in Europe, (3-8)% in East Asia, (9-33)% in the 
Middle East, 12% in Australia and 23% in South America 
• Incidence per 1000 person-years is approximately 5 in the 
overall UK and US populations, and 0.84 in pediatric patients 
aged 1-17 years in the UK 
• Evidence suggests an increase in GERD prevalence since 1995 
(p<0.0001), particularly in North America and East Asia. 
 
https://www.ncbi.nlm.nih.gov/pubmed/23853213 
Epidemiology 2   
http:// http://www.ncbi.nlm.nih.gov/pubmed/17151290 
Global distribution of the burden of GERD. Sample-size weighted 
mean estimates of the prevalence of at least weekly heartburn and/or 
regurgitation in each country. 
Risk Factors  
• Weight gain 
• Fatty foods 
• Caffeinated 
• Carbonated beverages 
• Alcohol 
• Tobacco smoking 
• Drugs 
• Hiatal hernia  
• Increasing body mass 
index  
• Zollinger-Ellison 
syndrome 
 
• A high blood calcium level (increase 
gastrin production) 
• Scleroderma and systemic sclerosis, 
which can feature esophageal 
dysmotility  
• Visceroptosis or Glénard syndrome  
• A variety of respiratory and laryngeal 
complaints (laryngitis, 
chronic cough, pulmonary 
fibrosis, earache, and asthma 
• Obstructive sleep apnea 
• Gallstones  
• H. pylori infection. 
 
https://en.wikipedia.org/wiki/Gastroesophageal_reflux_disease#Epidemiology 
Etiology 
• The presence of reflux implies LES incompetence, which may result 
from a generalized loss of intrinsic sphincter tone or from recurrent 
inappropriate transient relaxations 
• Transient LES relaxations are triggered by gastric distention or 
subthreshold pharyngeal stimulation  
• Factors that contribute to the competence of the gastroesophageal 
junction include the angle of the cardioesophageal junction, the 
action of the diaphragm, and gravity (i.e., an upright position) 
• Drugs that lower LES pressure include anticholinergics, 
antihistamines, tricyclic antidepressants, Ca channel 
blockers, progesterone, and nitrates. 
http://www.merckmanuals.com/professional/gastrointestinal-disorders/esophageal-and-swallowing-disorders/gastroesophageal-reflux-disease-gerd 
Mechanisms 
  
• A dysfunctional lower esophageal sphincter (LES) allows reflux 
of large amounts of gastric juice 
• Delayed gastric emptying can increase the volume and 
pressure in the reservoir until the valve mechanism is 
defeated, leading to GERD 
•  Esophageal defense mechanisms can be broken down into 2 
categories (i.e., esophageal clearance and mucosal resistance) 
• Abnormal peristalsis can cause inefficient and delayed acid 
clearance  
• The mucosal resistance factors classified into pre-epithelial, 
epithelial, and postepithelial defenses, and when the 
defenses fail, esophagitis and other complications of reflux 
disease arise. 
 http://emedicine.medscape.com/article/176595-overview#a2 
Classification 
(International Classification of Diseases (ICD)) 
https://www.tsoshop.co.uk/productimages/default.aspx?ISBN=9789241549165&FORMAT=3  http://apps.who.int/classifications/icd10/browse/2016/en#/XI 
XI Diseases of the digestive 
system   
 K20-K31 Diseases of 
oesophagus, stomach and         
                             duodenum   
 K21 Gastro-
oesophageal reflux disease  
Clinical Investigation  
Signs and Symptoms  
• Heartburn  
• Belching 
• Sour taste 
• Acid regurgitation 
• Nausea and vomiting 
• Chronic cough, 
wheezing 
• Difficulty or pain when 
swallowing 
 
• Sore throat, hoarseness or 
change in voice  
• Chest pain 
• Sudden excess of saliva 
• Chronic sore throat  
• Inflammation of the gums 
• Cavities 
• Breathlessness  
• Esophageal hemorrhage. 
http://www.aaaai.org/conditions-and-treatments/related-conditions/gastroesophageal-reflux-disease 
Clinical Investigation  
Signs and Symptoms: Typical and Atypical  
http://www.worldgastroenterology.org/guidelines/global-guidelines/gastroesophageal-reflux-disease/gastroesophageal-reflux-disease-english 
Clinical Investigation  
Signs and Symptoms:  Association with Tooth Erosion 
 
Frontal and maxillary occlusal views of severe tooth erosion 
caused by endogenous acid in a patient with GERD. 
https://www.hindawi.com/journals/ijd/2012/479850/ 
Clinical Investigation  
Extraesophageal Presentations 
• GERD can be considered as a potential co-factor in patients 
with asthma, chronic cough, or laryngitis 
• Careful evaluation for non-GERD causes should be undertaken 
in all of these patients  
• A diagnosis of reflux laryngitis should not be made based 
solely upon laryngoscopy findings.   
https://thumbs.dreamstime.com/z/diabetes-mellitus-diabetic-signs-symptoms-clipart-illustrations-showing-disease-such-as-weight-loss-extreme-tiredness-61592413.jpg 
Clinical Investigation  
Complications 
• Esophagitis occur in approximately 50% of patients (see the 
images below). 
• Degrees of esophagitis are described by the Savary-Miller 
classification as follows: 
• Grade I – Erythema 
• Grade II – Linear nonconfluent erosions 
• Grade III – Circular confluent erosions 
• Grade IV – Stricture or Barrett esophagus (Barrett esophagus 
with intestinal type metaplasia has malignant potential and is 
a risk factor for the development of esophageal 
adenocarcinoma).   
http://emedicine.medscape.com/article/176595-overview#a7 
Diagnosis  
Components 
• Clinical diagnosis (a detailed history points to the diagnosis; patients 
with typical symptoms may be given a trial of therapy; patients who 
do not improve, or have long-standing symptoms or symptoms of 
complications, should be studied) 
• Endoscopy for patients not responding to empiric treatment, with 
cytologic washings and biopsy of abnormal areas, is the test of 
choice  
• 24-h pH testing for patients with typical symptoms but normal 
endoscopy 
• Esophageal manometry may be used to guide pH probe placement 
and to evaluate esophageal peristalsis before surgical treatment. 
https://www.diabetes.org.uk/About_us/What-we-say/Diagnosis-ongoing-management-monitoring/New_diagnostic_criteria_for_diabetes/ 
Diagnosis  
Key Points  
• A presumptive diagnosis can be established in the setting of typical 
symptoms of heartburn and regurgitation  
• Patients with non-cardiac chest pain suspected due to GERD should 
have diagnostic evaluation before institution of therapy  
• Barium radiographs should not be performed to diagnose GERD 
• Upper endoscopy is not required in the presence of typical GERD 
symptoms 
• Endoscopy is recommended in the presence of alarm symptoms and 
for screening of patients at high risk for complications 
• Ambulatory esophageal reflux monitoring is indicated before 
consideration of endoscopic or surgical therapy. 
https://www.diabetes.org.uk/About_us/What-we-say/Diagnosis-ongoing-management-monitoring/New_diagnostic_criteria_for_diabetes/ 
Diagnosis  
Endoscopy and Biopsies 
• Endoscopy is not routinely needed if the case is typical and 
responds to treatment 
• Biopsies performed during gastroscopy may show: edema and basal 
hyperplasia; lymphocytic inflammation; neutrophilic inflammation 
(usually due to reflux or Helicobacter gastritis); eosinophilic 
inflammation (usually due to reflux); Goblet cell intestinal 
metaplasia or Barrett's esophagus; elongation of the papillae; 
thinning of the squamous cell layer; dysplasia, carcinoma. 
 
https://en.wikipedia.org/wiki/Gastroesophageal_reflux_disease#Epidemiology 
Diagnosis  
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https://en.wikipedia.org/wiki/Gastroesophageal_reflux_disease#Epidemiology 
Diagnosis  
Endoscopy and Biopsies: Peptic Esophagitis 
https://en.wikipedia.org/wiki/Gastroesophageal_reflux_disease#Epidemiology 
Diagnosis  
Endoscopy and Biopsies: Barrett Esophagus 
http://www.gastrointestinalatlas.com/imagenes/BarrettAguach3.jpg 
Diagnosis  
Esophageal Manometry 
• Esophageal manometry defines the function of the les LES and the 
esophageal body (peristalsis) and is essential for correctly 
positioning the probe for the 24-hour pH monitoring 
• Indications for esophageal manometry and prolonged pH 
monitoring include the following: 
• Persistence of symptoms while taking adequate antisecretory 
therapy, such as PPI therapy 
• Recurrence of symptoms after discontinuation of acid-reducing 
medications 
• Investigation of atypical symptoms, such as chest pain or asthma, 
in patients without esophagitis 
• Confirmation of the diagnosis in preparation for antireflux 
surgery. 
http://emedicine.medscape.com/article/176595-workup#c9 
Diagnosis  
Ambulatory 24-Hour pH Monitoring 1 
• Ambulatory 24-hour pH monitoring is the criterion standard in 
establishing a diagnosis of GERD, with a sensitivity of 96% and a 
specificity of 95% 
• Ambulatory 24-hour pH monitoring quantifies the gastroesophageal 
reflux and allows a correlation between the symptoms of reflux and 
the episodes of reflux  
• Patients with endoscopically confirmed esophagitis do not need pH 
monitoring to establish a diagnosis of GERD. 
http://emedicine.medscape.com/article/176595-workup#c9 
Diagnosis  
Ambulatory 24-Hour pH Monitoring 2 
http://image.slidesharecdn.com/git-gerd-08-1223103354892827-8/95/git-gerd-08-42-728.jpg?cb=1223078215 
Normal 
GERD 
Diagnosis  
Ambulatory 24-Hour pH Monitoring 3 
https://www.hindawi.com/journals/ijd/2012/479850/fig1/ 
Pattern of sleep-related esophageal acid exposure in a patient 
with erosive esophagitis. Night-time acid reflux during supine 
sleep leads to pH levels <4 that are continuous and sustained.  
Diagnosis  
Imaging 
• Plain radiographic findings are not useful in evaluating patients for 
GERD, but they are helpful in evaluating the pulmonary status  
• Chest images may demonstrate a large hiatal hernia, but small 
hernias can be easily missed 
• Upper gastrointestinal (GI) contrast-enhanced studies with double-
contrast techniques are the initial radiologic procedure of choice in 
the workup of the patient in whom GERD is suggested  
• Gastric-emptying studies may be worthwhile in the evaluation of 
patients in whom delayed gastric emptying is believed to contribute 
to the manifestation of GERD symptoms   
http://emedicine.medscape.com/article/176595-workup#c9 
Diagnosis  
Radiography: Gastroesophageal Reflux  
http://emedicine.medscape.com/article/176595-overview#a2 
Barium esophagogram 
demonstrating 
gastroesophageal reflux 
with the patient in the 
upright position. 
Diagnosis  
Radiography: Hiatal hernia 
http://emedicine.medscape.com/article/176595-overview#a2 
Diagnosis  
Computed tomography:  Herniated Stomach 
http://emedicine.medscape.com/article/176595-overview#a2 
Diagnosis  
Intraluminal Esophageal Electrical Impedance 1 
• Intraluminal esophageal electrical impedance (EEI), a newer test, 
is useful for detecting both acid reflux and nonacid reflux by 
measuring retrograde flow in the esophagus 
• Gastroesophageal reflux episodes as brief as 15 seconds may be 
measured (see the image below) 
• In adult studies, impedance measurements have been used in 
conjunction with 24-hour intraesophageal pH monitoring in 
order to provide a more complete picture of bolus movement in 
the esophagus 
• EEI has not been thoroughly validated, and normal values have 
not been determined in the pediatric age group. 
http://emedicine.medscape.com/article/176595-workup#c9 
Diagnosis  
Intraluminal Esophageal Electrical Impedance 2 
• The image is a representation of 
concomitant intraesophageal pH and 
esophageal electrical impedance 
measurements 
• The vertical solid arrow indicates 
commencement of a nonacid 
gastroesophageal reflux (GER) episode 
(diagonal arrow) 
• The vertical dashed arrow indicates the 
onset of a normal swallow. 
http://emedicine.medscape.com/article/176595-workup#c9 
Diagnosis  
Differential Conditions 
• Achalasia 
• Acute Gastritis 
• Antral Web Cholelithiasis 
• Chronic Gastritis 
• Coronary Artery Atherosclerosis 
• Esophageal Cancer 
• Esophageal Motility Disorders 
• Esophageal Spasm 
 
• Esophagitis 
• Gallstones (Cholelithiasis) 
• Helicobacter Pylori Infection 
• Hiatal Hernia 
• Intestinal Malrotation 
• Intestinal Motility Disorders 
• Irritable Bowel Syndrome 
• Peptic Ulcer Disease 
http://emedicine.medscape.com/article/176595-differential 
Management 
Key Moments 
• Treatment involves a stepwise approach 
• The goals are to control symptoms, to heal esophagitis, and to 
prevent recurrent esophagitis or other complications 
• The treatment is based on lifestyle modification and control of 
gastric acid secretion through medical therapy with antacids or 
PPIs or surgical treatment with corrective antireflux surgery 
• Approximately 80% of patients have a recurrent but 
nonprogressive GERD that is controlled with medications 
• Identifying the 20% of patients who have a progressive form of 
the disease is important, because they may develop severe 
complications, such as strictures or Barrett esophagus 
• . For patients who develop complications, surgical treatment 
should be considered at an earlier stage. 
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Management 
Lifestyle Modification 
• Weight loss is recommended for patients who are overweight 
or have had recent weight gain  
• Head of bed elevation and avoidance of meals 2–3 h before 
bedtime   
• Avoiding large meals 
• Routine global elimination of food that can trigger reflux 
(including chocolate, caffeine, alcohol, acidic and/or spicy 
foods) is not recommended.    
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Management 
Medications: Proton Pump Inhibitors 1 
• An 8-week course of proton pump inhibitors (PPIs) is the 
therapy of choice for symptom relief and healing of erosive 
esophagitis  
• Traditional delayed release PPIs should be administered 30–
60 min before meal for maximal pH control 
• PPI therapy should be initiated at once a day dosing, before the 
first meal of the day 
• For patients with partial response to once daily therapy, tailored 
therapy with adjustment of dose timing and/or twice daily 
dosing should be considered in patients with night-time 
symptoms, variable schedules, and/or sleep disturbance.  
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Management 
Medications: Proton Pump Inhibitors 2 
• In patients with partial response to PPI therapy, increasing the 
dose to twice daily therapy or switching to a different PPI may 
provide additional symptom relief  
• Maintenance PPI therapy should be administered for patients 
who continue to have symptoms after PPI is discontinued, and 
in patients with complications including erosive esophagitis and 
Barrett’s esophagus 
• For patients who require long-term PPI therapy, it should be 
administered in the lowest effective dose, including on demand 
or intermittent therapy.   
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Management 
Medications: Proton Pump Inhibitors 3 
• Non-responders to PPI should be referred for evaluation  
• PPIs are safe in pregnant patients if clinically indicated. 
(Conditional recommendation, moderate level of evidence) 
• PPIs are safe in pregnant patients if clinically indicated. 
(Conditional recommendation, moderate level of evidence) 
• Newer PPIs may offer dosing flexibility relative to meal timing  
• There are no major differences in efficacy between the different 
PPIs 
• Available PPIs include omeprazole, lansoprazole, rabeprazole, 
and esomeprazole.  
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Management 
Medications: Proton Pump Inhibitors 4 
Potential risks associated with PPIs 
• Switching PPIs can be considered in the setting of side-effects  
• Patients with known osteoporosis can remain on PPI therapy  
• PPI therapy can be a risk factor for Clostridium difficile 
infection, and should be used with care in patients at risk  
• Short-term PPI usage may increase the risk of community-
acquired pneumonia  
• PPI therapy does not need to be altered in concomitant 
clopidogrel users as there does not appear to be an increased 
risk for adverse cardiovascular events. 
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Management 
Medications: H2-receptor antagonist  
• H2-receptor antagonist (H2RA) therapy can be used as a 
maintenance option in patients without erosive disease if 
patients experience heartburn relief 
• Bedtime H2RA therapy can be added to daytime PPI therapy in 
selected patients with objective evidence of night-time reflux if 
needed, but may be associated with the development of 
tachyphlaxis after several weeks of use 
• Additional H2RA therapy has been reported to be useful in 
patients with severe disease (particularly those with Barrett 
esophagus) who have nocturnal acid breakthrough 
• Options include ranitidine, cimetidine, famotidine, and 
nizatidine.   
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Management 
Medications: Prokinetic Medications and Reflux Inhibitors 
• Prokinetic agents are somewhat effective but only in patients 
with mild symptoms; other patients usually require additional 
acid-suppressing medications, such as PPIs 
• The usual regimen in adults is metoclopramide, 10 mg/day 
orally 
• Long-term use of prokinetic agents may have serious, even 
potentially fatal, complications and should be discouraged  
• There is no role for sucralfate in the non-pregnant GERD 
patient.  
http://emedicine.medscape.com/article/176595-treatment#d11 http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Management 
Overtreatment 
• The use of acid suppression therapy is a common response to 
GERD symptoms and many patients get more of this kind of 
treatment than their individual case merits 
• The overuse of this treatment is a problem because of the side 
effects and costs which the patient will have from undergoing 
unnecessary therapy, and patients should not take more 
treatment than they need  
• In some cases, a person with GERD symptoms can manage them 
by taking over-the-counter drugs and making lifestyle changes, 
that is often safer and less expensive than taking prescription 
drugs 
• Some guidelines recommend trying to treat symptoms with 
an  H2-receptor antagonists  before using a proton-pump 
inhibitor because of cost and safety concerns. 
https://en.wikipedia.org/wiki/Gastroesophageal_reflux_disease#Epidemiology 
Management 
Surgical Options 
• Surgical therapy is a treatment option for long-term therapy 
• Surgical therapy is generally not recommended in patients who 
do not respond to PPI therapy 
• All patients should undergo preoperative manometry to rule 
out achalasia or scleroderma-like esophagus  
• Surgical therapy is as effective as medical therapy for carefully 
selected patients when performed by an experienced surgeon 
• Obese patients contemplating surgical therapy should be 
considered for bariatric surgery  
• The usage of current endoscopic therapy or transoral 
incisionless fundoplication cannot be recommended as an 
alternative to medical or traditional surgical therapy. 
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/ 
Prognosis  
• Most patients do well with medications, although a relapse 
after cessation of medical therapy is common and indicates 
the need for long-term maintenance therapy 
• Identifying the subgroup of patients who may develop the 
most serious complications and treating them aggressively is 
important 
• Surgery at an early stage is most likely indicated in these 
patients   
• Most cases of gastroesophageal reflux in infants and very 
young children are benign and respond to conservative 
nonpharmacologic treatment.    
http://emedicine.medscape.com/article/176595-overview#a7 
Prophylaxis  
• Lifestyle changes that help treat GERD symptoms are effective 
preventative measures 
• These include: 
• Not smoking 
• Avoiding foods and drinks that trigger acid reflux 
• Eating sensible portions 
• Maintaining a healthy weight 
• Wearing loose-fitting clothing 
• Elevating the head during sleep. 
https://en.wikipedia.org/wiki/Diabetes_mellitus#Prevention 
Abbreviations  
EEI - esophageal electrical impedance 
GI - gastrointestinal  
H2RA - H2-receptor antagonist 
LES - lower esophageal sphincter  
PPIs - proton pump inhibitors 
GERD - gastroesophageal reflux disease 
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• Diagnosis and Management of Gastroesophageal Reflux 
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